THE TAPE

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

$21.59▲ +0.75%
Last close
Relative strength
89RS
of 99, against every stock▲ +9 on the month
Powering up
Developing
+17.3%
six months against Pharmaceutical Preparations
52-week range
−1.2%
from the high
$13.91$21.86
Setup
blue skyclimbing
+13.0%
against the pivot at $19.10
73 days
Jan 28 · not confirmed
No US GAAP filings to read.
11/16 O 21.73 H 21.86 L 21.56 Vol 3.3M
Draw
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

RS89
vs pivot+13.04%
Tightening0.93×
Dry-up0.84×
Up/down vol0.08
From high1%
climbing6 of 9checks
Previous breakout trailed out ▼ −6.25% in Sep
Powering up
Support and resistance
Support below
$20.60
-4.6% · tested 3× · last 3 sessions ago
Resistance above
None within the last 120 sessions

Prices this stock has turned at three or more times in the last 120 sessions, with how many times. Where buyers and sellers showed up before, not a forecast, an entry or a stop.

The read

The base has run 4.0 weeks and fell 7% from its ceiling at its deepest. The pivot is $19.10, and the stock closed 13.0% above that pivot. Its relative strength rating is 89.

Against its industry
DevelopingAhead of its industry over one and three months and not behind over six, in an industry at least partly aligned.
One month against its industry
+5.1%
Three months against its industry
+38.2%
Six months against its industry
+17.3%

Read against an equal-weighted index of Pharmaceutical Preparations, which is +10.9% against the S&P 500 over six months Partly aligned.

Also on
Peers
Catalyst roadmap
73
days
Earnings in 73 days (not yet confirmed)
Jan 28, 2027
  1. Earningstentativein 73d
    Quarterly earnings
    Jan 28, 2027
How it moves on earnings

No past reports on record for this company yet.

The business

No figures in US GAAP filings for this company. Most foreign listings report under international standards, which this does not read.

Tracked funds

Held by 1 of 46 tracked funds at the end of Q3 2026.

Last quarter: 1 bought new.

Checking your subscription…

From 13F filings, which show long stock only and arrive up to 45 days after the quarter. The broad quant funds are left out.

Flagged by the market sweep

Nothing flagged for this company on the last market sweep.

In the news
Insiders
Bought on the open market
0
Sold on the open market
22
$15,224,644 total

Sold: Platford Giles Richard, Bitetti Teresa Marie, Duprey Lauren Rusckowski, Plump Andrew Stewart, Greenway Nicola Deidre Petal, Shannon Elaine Mary, Farajallah Awny Samaan Botros, Ibrahim Ramy Riad Ahmed, Pacheco Rhonda Janice, Pignagnoli Agosti Marcello, Ricci Gabriele, Kim Julie So-Young, Furney Natalie Anne Marie.

Not counted above: 25 filings for awards, option exercises, gifts or shares withheld to pay tax. Those follow a vesting schedule nobody chose the timing of, and counting them as selling is how that number gets misread.

Most recent filings
2026-11-04 Platford Giles Richard · President, IBUsell55,617$1,162,395
2026-11-02 Bitetti Teresa Marie · President, OBUsell46,609$973,662
2026-09-14 Duprey Lauren Rusckowski · Chief Transformation Officersell34,535$640,279
2026-09-02 Plump Andrew Stewart · President, R&D, Directorsell116,191$2,148,372
2026-08-19 Plump Andrew Stewart · President, R&D, Directorsell19,651$363,347
2026-08-18 Greenway Nicola Deidre Petal · Chief Human Resources Officersell12,980$235,118
2026-08-11 Shannon Elaine Mary · Pres., Global Supply & Qualitysell20,363$357,371
2026-08-10 Farajallah Awny Samaan Botros · Chief Medical Officersell14,006$239,503

From SEC Form 4, filed within two business days of the trade. What was filed, not what it means.

What lines up

6 of 9 published checks currently line up. This is a count, not a probability — nothing on this site measures how often a setup works.

Relative strength of 80 or better
Above its 50-day line
Above its 200-day line
Averages fully stacked
Within 5% of its pivot
Range tightening through the base
Volume drying up through the base
More up-volume than down-volume
Within 15% of its 52-week high
What analysts expect
Strong buy0
Buy3
Hold0
Sell0
Strong sell0

These are analysts’ estimates, not ours, and not a projection this site endorses. They are published here because what the sell side expects is itself a fact about the market.

Checking your subscription…

Gamma concentration

Checking your subscription…

X-ray
4w · 7%

The most recent of 4 completed bases.

Checking your subscription…

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. A stock on a screen matches a shape; that is not a prediction. Prices are end-of-day, not live.

What that means, in full
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) — The Tape